NCT02503176
Terminated
Phase 3
An Extension Study of KCT-0809 in Dry Eye Patients With Sjögren's Syndrome
ConditionsDry Eye With Sjögren's Syndrome
InterventionsKCT-0809 ophthalmic solution
Overview
- Phase
- Phase 3
- Intervention
- KCT-0809 ophthalmic solution
- Conditions
- Dry Eye With Sjögren's Syndrome
- Sponsor
- Kissei Pharmaceutical Co., Ltd.
- Primary Endpoint
- Incidences of adverse events
- Status
- Terminated
- Last Updated
- 8 years ago
Overview
Brief Summary
The purpose of this study is to evaluate of the long-term safety and efficacy of KCT-0809 in dry eye patients with Sjögren's syndrome.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Dry eye patients with Sjögren's syndrome finished KCT1301 study
Exclusion Criteria
- •Patients with poor adherence to medication of study drug in KCT1301 study
Arms & Interventions
KCT-0809
Intervention: KCT-0809 ophthalmic solution
Outcomes
Primary Outcomes
Incidences of adverse events
Time Frame: 52 weeks
Secondary Outcomes
- Score of the corneal staining(52 weeks)
Similar Trials
Completed
Phase 3
A Long-term Study of KCT-0809 in Dry Eye Patients With Sjögren's SyndromeDry Eye With Sjögren's SyndromeNCT02503163Kissei Pharmaceutical Co., Ltd.
Completed
Phase 3
A Phase III Study of KCT-0809 in Dry Eye Patients With Sjögren's SyndromeDry Eye With Sjögren's SyndromeNCT02503189Kissei Pharmaceutical Co., Ltd.
Completed
Phase 2
A Phase II Study of KCT-0809 in Patients With Dry Eye SyndromeDry Eye SyndromesNCT01427816Kissei Pharmaceutical Co., Ltd.180
Completed
Phase 3
Study to Evaluate the Efficacy and Safety of CKD-352Dry Eye DiseaseNCT04548427Chong Kun Dang Pharmaceutical283
Unknown
Phase 3
Study to Evaluate the Efficacy and Safety of CKD-350Dry Eye SyndromeNCT02777723Chong Kun Dang Pharmaceutical138